查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387442

紅斑治療市場報告：到 2030 年的趨勢、預測和競爭分析

Erythromelagia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

紅斑性肢痛症治療的趨勢與預測

預計 2024 年至 2030 年，全球紅斑治療市場將以 5.8% 的年複合成長率成長。該市場的主要驅動力是成紅血球發育不全患者數量的增加、精準醫療投資的增加以及藥物研發技術的進步。全球紅斑治療市場的未來充滿希望，醫院、居家醫療和專科診所市場充滿機會。

紅斑治療市場洞察

Lucintel 預測，由於可以使用有效的藥物來控制成紅血球發育不全的症狀，因此在預測期內藥物治療將繼續在該領域佔據主導地位。

由於對基礎設施和專業知識的需求不斷增加，為紅血球再生障礙患者提供全面治療，醫院仍將是該市場中最大的部分。

由於研究型大學、醫學院和製藥公司數量不斷增加，北美仍是預測期內最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球紅斑治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球紅斑治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按治療分類的全球紅斑治療市場
    • 藥品
    • 外科手術
  • 按類型分類的全球紅斑治療市場
    • 原發性紅斑疼痛
    • 續發性紅斑疼痛
  • 按藥物分類的全球紅斑治療市場
    • 利多卡因
    • 辣椒素
    • 雙氯芬酸
    • 溴莫尼定
    • 米索前列醇
    • 其他
  • 按最終用途分類的全球紅斑治療市場
    • 醫院
    • 居家護理
    • 專科診所
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球紅斑治療市場（按地區）
  • 北美紅斑治療市場
  • 歐洲紅斑治療市場
  • 亞太紅斑治療市場
  • 其他區域紅斑治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球紅斑治療市場按治療方式的成長機會
    • 按類型分類的全球紅斑治療市場成長機會
    • 全球紅斑治療市場藥物成長機會
    • 按最終用途分類的全球紅斑治療市場成長機會
    • 按地區分類的全球紅斑治療市場成長機會
  • 全球紅斑治療市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球紅斑治療市場的產能
    • 全球紅斑治療市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals
簡介目錄

Erythromelagia Treatment Trends and Forecast

The future of the global erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine, and advancement in drug discovery technologies.

A more than 150-page report is developed to help in your business decisions.

Erythromelagia Treatment by Segment

The study includes a forecast for the global erythromelagia treatment by treatment, type, drug, end-use, and region.

Erythromelagia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Medication
  • Surgery

Erythromelagia Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Primary Erythromelalgia
  • Secondary Erythromelalgia

Erythromelagia Treatment Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Lidocaine
  • Capsaicin
  • Diclofenac
  • Brimonidine
  • Misoprostol
  • Others

Erythromelagia Treatment Market by End-Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Erythromelagia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Erythromelagia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies erythromelagia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the erythromelagia treatment companies profiled in this report include-

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals

Erythromelagia Treatment Market Insights

Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Within this market, hospital will remain the largest segment due to growing need of infrastructure and expertise to provide comprehensive care for patients with erythromelalgia.

North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Features of the Global Erythromelagia Treatment Market

Market Size Estimates: Erythromelagia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Erythromelagia treatment market size by various segments, such as by treatment, type, drug, end-use, and region in terms of value ($B).

Regional Analysis: Erythromelagia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatments, types, drugs, end-uses, and regions for the erythromelagia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the erythromelagia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for erythromelagia treatment market?

Answer: The global erythromelagia treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the erythromelagia treatment market?

Answer: The major drivers for this market are growing number of patients with erythromelalgia, rising investment in precision medicine and advancement in drug discovery technologies.

Q3. What are the major segments for erythromelagia treatment market?

Answer: The future of the erythromelagia treatment market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q4. Who are the key erythromelagia treatment market companies?

Answer: Some of the key erythromelagia treatment companies are as follows:

  • Teva Pharmaceutical Industries
  • Xenon
  • Biogen
  • ICAGEN
  • Pfizer
  • Zydus Cadila
  • ANI Pharmaceuticals

Q5. Which erythromelagia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that medication will remain the larger segment over the forecast period due to availablilty of medications, which are effective in managing the symptoms of the disease.

Q6. In erythromelagia treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to rising number of research universities, medical schools, and pharmaceutical firms in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the erythromelagia treatment market by treatment (medication and surgery), type (primary erythromelalgia and secondary erythromelalgia), drug (lidocaine, capsaicin, diclofenac, brimonidine, misoprostol, and others), end-use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Erythromelagia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Erythromelagia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Erythromelagia Treatment Market by Treatment
    • 3.3.1: Medication
    • 3.3.2: Surgery
  • 3.4: Global Erythromelagia Treatment Market by Type
    • 3.4.1: Primary Erythromelalgia
    • 3.4.2: Secondary Erythromelalgia
  • 3.5: Global Erythromelagia Treatment Market by Drug
    • 3.5.1: Lidocaine
    • 3.5.2: Capsaicin
    • 3.5.3: Diclofenac
    • 3.5.4: Brimonidine
    • 3.5.5: Misoprostol
    • 3.5.6: Others
  • 3.6: Global Erythromelagia Treatment Market by End-Use
    • 3.6.1: Hospitals
    • 3.6.2: Homecare
    • 3.6.3: Specialty Clinics
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Erythromelagia Treatment Market by Region
  • 4.2: North American Erythromelagia Treatment Market
    • 4.2.2: North American Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.3: European Erythromelagia Treatment Market
    • 4.3.1: European Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.3.2: European Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.4: APAC Erythromelagia Treatment Market
    • 4.4.1: APAC Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.4.2: APAC Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.5: ROW Erythromelagia Treatment Market
    • 4.5.1: ROW Erythromelagia Treatment Market by Treatment: Medication and Surgery
    • 4.5.2: ROW Erythromelagia Treatment Market by End-Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Erythromelagia Treatment Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Erythromelagia Treatment Market by Type
    • 6.1.3: Growth Opportunities for the Global Erythromelagia Treatment Market by Drug
    • 6.1.4: Growth Opportunities for the Global Erythromelagia Treatment Market by End-Use
    • 6.1.5: Growth Opportunities for the Global Erythromelagia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Erythromelagia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Erythromelagia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Erythromelagia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceutical Industries
  • 7.2: Xenon
  • 7.3: Biogen
  • 7.4: ICAGEN
  • 7.5: Pfizer
  • 7.6: Zydus Cadila
  • 7.7: ANI Pharmaceuticals